Biomea Fusion, Inc.
Biomea Fusion, Inc. (Nasdaq: BMEA) is a clinical-stage biotechnology company developing oral small-molecule medicines for diabetes, obesity and other metabolic diseases. Its lead candidate, icovamenib, is an oral menin inhibitor being studied for type 1 and type 2 diabetes, with additional research exploring potential… From the company’s description.
In fiscal 2025, Biomea Fusion, Inc. reported a net loss of $61.80M. Operations used $70.37M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Biomea Fusion, Inc. does
In the company’s own words
Biomea Fusion, Inc. (Nasdaq: BMEA) is a clinical-stage biotechnology company developing oral small-molecule medicines for diabetes, obesity and other metabolic diseases. Its lead candidate, icovamenib, is an oral menin inhibitor being studied for type 1 and type 2 diabetes, with additional research exploring potential effects in obesity. Its other principal candidate, BMF-650, is an investigational oral GLP-1 receptor agonist in development for obesity. The company’s clinical programs include Phase II studies of icovamenib in type 2 diabetes and a Phase I study of BMF-650 in overweight or obese participants. Biomea has no products approved for commercial sale and has not generated revenue. Following a 2025 strategic realignment, it concentrates its internal development efforts on metabolic diseases and is concluding oncology studies, while considering partnerships for oncology assets. It relies on third parties to manufacture candidates for preclinical and clinical research. Biomea had approximately 40 employees in 2025.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SAN CARLOS, CA
- Fiscal year end
- December
- CIK
- 1840439
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Biomea Fusion, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Biomea Fusion, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Biomea Fusion, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Biomea Fusion, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Biomea Fusion, Inc.'s last four quarterly filings that the numbers alone won't show?”